I've always thought that that BP would take out both Acadia and Neuren - but I'm starting to think - why would you take out Acadia?
Umm…how about
- Likely annual sales revenue > US$1bn going forward (2023 Nuplazid revenue was US$550m).
- Recent court patent wins which suggest a long revenue runway remains for Nuplazid.
- No near term competitors + 7 years orphan exclusivity protecting Daybue revenue.
- Additional sales revenue to be generated from ex-US Daybue sales.
- Potential cost savings for a Big Pharma.
- Deep knowledge of Rett syndrome and its US patients, families and practitioners.
- Has Phase 3 asset of ACP-101 in Hyperphagia in Prader-Willi syndrome, due to read out in 2026, which is likely to succeed. There are no current treatments.
- Has Phase 2/3 asset of ACP-204 in Alzheimer’s disease psychosis (estimated US patient population of >3 m).
- Has global rights to NNZ-2591 in both Rett syndrome and Fragile-X syndrome.
- Preclinical programs thrown in for free.
Neuren - where to from here ?, page-49
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.70 |
Change
-0.310(2.38%) |
Mkt cap ! $1.623B | |||
| Open | High | Low | Value | Volume |
| $12.80 | $12.90 | $12.69 | $5.154M | 403.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4631 | $12.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.76 | 1060 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |